Physician profile
Danielle Warren
NPI 1033394044
$11,466.50
in general payments reported to CMS, 2019-2025
32 companies · $2,589 in 2025
The $2,589 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $2,153 · 2023: $2,277 · 2024: $2,885 · 2025: $2,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,373 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,373.41 |
| Education | $377.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,345.65 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,248.21 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,062.57 | 2022-2025 | Sotyktu |
| Abbvie INC. | $1,044.77 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $958.37 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $890.38 | 2021-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $785.06 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $596.46 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $586.05 | 2021-2025 | Opzelura |
| Pfizer INC. | $493.09 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $401.95 | 2023-2025 | Zoryve |
| Genzyme Corporation | $356.59 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $317.60 | 2022-2025 | |
| Galderma Laboratories, L.P. | $255.04 | 2022-2025 | Aklief, Epsolay, Nemluvio |
| Dermavant Sciences, INC. | $217.42 | 2023-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $210.15 | 2021-2025 | Anzupgo, Spevigo, Adbry |
| Amgen INC. | $125.84 | 2021-2025 | Otezla, Otezla |
| Vyne Pharmaceuticals INC. | $121.48 | 2021 | |
| Almirall LLC | $72.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.00 | 2023-2025 | Spevigo |
| Epi Health, LLC | $55.22 | 2021 | |
| Organon LLC | $51.01 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $41.35 | 2024 | Ycanth |
| Boston Scientific Corporation | $33.39 | 2025 | Avvigo Guidance System, Rotapro |
| Kyowa Kirin, INC. | $26.44 | 2025 | |
| Merz North America, INC. | $21.08 | 2021 | |
| Genentech USA, INC. | $17.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.96 | 2024 | Simlandi |
| Biowound Solutions, INC. | $14.47 | 2025 | Bio-Connekt |
| Botanix Sb INC | $13.61 | 2025 | Sofdra |
| Nabriva Therapeutics, Plc | $13.10 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.